SCHEMBL25514196

SCHEMBL25514196

Cc1cc2c(n1Cc1ccc(C(=O)O)cc1)CCCC2=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.54
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
ALDH1A1 P00352 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
KDM4E B2RXH2 3/20 0.54
POLB P06746 2/20 0.54
USP2 O75604 1/20 0.54
GAA P10253 1/20 0.54
MAPT P10636 1/20 0.54
THRB P10828 1/20 0.54
NR4A1 P22736 1/20 0.54
APEX1 P27695 1/20 0.54
APOBEC3A P31941 1/20 0.54
RECQL P46063 1/20 0.54
HIF1A Q16665 1/20 0.54
APOBEC3G Q9HC16 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
LMNA P02545 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25514199 0.90 BRD4 (0.51) BRD4MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL21410459 0.85 BRD4 (0.76) BRD4MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL21410171 0.83 BRD4 (0.50) BRD4MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL25514178 0.83 BRD4 (0.54) BRD4MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL25514185 0.83 BRD4 (0.54) BRD4MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL25514004 0.81 BRD4 (0.52) BRD4MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL25514182 0.80 BRD4 (0.51) BRD4MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL21413199 0.78 BRD4 (0.45) BRD4MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL23174922 0.78 BRD4 (0.44) BRD4MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL1053390 0.77 HPGD (0.50) BRD4MEN1KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159554-A1 COMPOUND WITH ANTICANCER ACTIVITY KYOWA KIRIN CO., LTD. (JP) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159554-A1 COMPOUND WITH ANTICANCER ACTIVITY TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 BRD4 2025/4885MEN1 41/4885KMT2A 2349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.